Evaxion announced a collaboration with Afrigen Biologics (Afrigen).

Evaxion announced the initiation of a novel pipeline program, EVX-B3, an AI-designed vaccine candidate against an undisclosed bacterial pathogen.

In this study, we demonstrate how the addition of an antigen-presenting cell (APC) binding molecule to DNA-encoded cancer neoepitopes improves neoepitope-specific T-cell responses and the anti-tumor efficacy of plasmid DNA vaccines.

Evaxion has achieved a groundbreaking milestone in vaccine discovery with the validation of its AI-powered vaccine discovery platform, EDEN.

Evaxion has hired a new Chief Executive Officer (“CEO”) to accelerate the strategic development and execution of the vast business opportunities at hand after having matured the Company’s AI platforms over the past 15 years.

With autumn on the horizon, Evaxion is poised to take center stage at the season's pivotal conferences. We look forward to presenting our business, engaging with fellow biotech innovators, and drawing inspiration. Click here to learn more about all our upcoming conferences.

Evaxion presents promising results of EVX-B1 at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA.

We are thrilled about our first-ever Research & Development (R&D) Day at our Hørsholm HQ in late May. The event was a resounding success, featuring talks by Evaxion scientists and collaborators sharing previously unreleased preclinical data.

Evaxion is set to present promising clinical data from its EVX-01 Phase 1 clinical trial in metastatic melanoma on June 3, at the 2023 ASCO annual meeting, in Chicago, Illinois.

Evaxion has developed a new proprietary AI platform technology ObsERV™ to identify a new source of targets for personalized cancer therapy, potentially enabling treatment of patients that are currently considered unresponsive to cancer immunotherapy.